The Future of GDNF in Parkinson's Disease

• Type of Material: Article
• Authors: Frederic P. Manfredsson, Barrow Neurological Institute; Nicole K. Polinski, The Michael J. Fox Foundation for Parkinson's Research; Thyagarajan Subramanian, Pennsylvania State University; Nicholas Boulis, Emory University; Dustin R. Wakeman, Virscio, Inc.; Ronald J. Mandel, University of Florida
• Language: English
• Date: 2020-12-07
• Publisher: FRONTIERS MEDIA SA
• Publication Version: Final Published Version
• Copyright Statement: © 2020 Manfredsson, Polinski, Subramanian, Boulis, Wakeman and Mandel.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.3389/fnagi.2020.593572
• Title of Journal or Parent Work: FRONTIERS IN AGING NEUROSCIENCE
• Volume: 12
• Start Page: 593572
• End Page: 593572
• Keywords: Neurosciences & Neurology; DEGENERATION; GDNF (glial cell line-derived neurotrophic factor); NIGRAL DOPAMINE NEURONS; NEUROLOGICAL DISORDERS; Neurosciences; NEUROTROPHIC FACTOR GDNF; Geriatrics & Gerontology; Science & Technology; GENE-THERAPY; TYROSINE-HYDROXYLASE; Life Sciences & Biomedicine; INFUSION; CDNF PROTECTS; DOUBLE-BLIND; Parkinson's disease; clinical trial (2.172); neurturin; gene therapy (GT); neurotrophic factor; RAT MODEL
• Research Categories: Gerontology; Biology, Genetics; Biology, Neuroscience